Improvement in hepatic encephalopathy with rifaximin is associated with distinct changes in the metagenomic species in the saliva and stool microbiome and a reduction in systemic inflammation - results of the rifsys randomized controlled trial. - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement
Communication Dans Un Congrès Année : 2018

Improvement in hepatic encephalopathy with rifaximin is associated with distinct changes in the metagenomic species in the saliva and stool microbiome and a reduction in systemic inflammation - results of the rifsys randomized controlled trial.

Domaines

Sciences du Vivant [q-bio]

Migration ProdInra  : Connectez-vous pour contacter le contributeur

https://hal.inrae.fr/hal-02734343

Soumis le : mardi 2 juin 2020-13:43:19

Dernière modification le : mardi 18 janvier 2022-14:26:07

Fichier non déposé

Dates et versions

hal-02734343 , version 1 (02-06-2020)

Identifiants

  • HAL Id : hal-02734343 , version 1
  • PRODINRA : 465392
  • WOS : 000451622600025

Citer

Vishal C. Patel, Mark J. Mcphail, Ane Zamalloa, Sidsel Stoy, Godhev K. Manakkat Vijay, et al.. Improvement in hepatic encephalopathy with rifaximin is associated with distinct changes in the metagenomic species in the saliva and stool microbiome and a reduction in systemic inflammation - results of the rifsys randomized controlled trial.. 68. Annual Meeting of the merican-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver, Oct 2017, Washington, DC, United States. pp.2. ⟨hal-02734343⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INRA UNIV-PARIS-SACLAY INRAE
16 Consultations
0 Téléchargements

Partager

More